论文部分内容阅读
在多数企业通过规模并购、开发新兴市场、拓宽经营业务等策略实现销售增长的同时,非专利药物竞争、结构调整、药品召回以及诉讼等问题却大大影响了企业的净收益表现。长远看来,医药业的整合风仍将继续。行业发展将呈现出两大趋势,一些企业聚焦于新产品的研发,另一些则致力于非专利药物的生产,那些无所作为的企业很可能在未来的市场竞争中惨遭淘汰。
While most enterprises achieve sales growth through such strategies as scale mergers and acquisitions, developing emerging markets and expanding their business operations, the issues of non-patent drug competition, structural adjustment, drug recalls and litigation have greatly affected their net income performance. In the long run, the consolidation of the pharmaceutical industry will continue. There will be two major trends in the development of the industry. Some companies will focus on the research and development of new products while others will focus on the production of generic drugs. Those doing nothing will likely be eliminated in the future market competition.